Abbott Laboratories
ABT
$133.58
-$0.36-0.27%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 10.36B | 10.97B | 10.64B | 10.38B | 9.96B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.36B | 10.97B | 10.64B | 10.38B | 9.96B |
| Cost of Revenue | 4.46B | 4.97B | 4.70B | 4.52B | 4.46B |
| Gross Profit | 5.90B | 6.00B | 5.94B | 5.85B | 5.50B |
| SG&A Expenses | 2.91B | 2.74B | 2.76B | 2.78B | 2.83B |
| Depreciation & Amortization | 420.00M | 465.00M | 470.00M | 471.00M | 472.00M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.48B | 8.93B | 8.64B | 8.45B | 8.45B |
| Operating Income | 1.87B | 2.04B | 1.99B | 1.93B | 1.52B |
| Income Before Tax | 1.78B | 2.03B | 1.94B | 1.61B | 1.44B |
| Income Tax Expenses | 453.00M | -7.20B | 294.00M | 305.00M | 211.00M |
| Earnings from Continuing Operations | 1.33B | 9.23B | 1.65B | 1.30B | 1.23B |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.33B | 9.23B | 1.65B | 1.30B | 1.23B |
| EBIT | 1.87B | 2.04B | 1.99B | 1.93B | 1.52B |
| EBITDA | 2.63B | 2.85B | 2.80B | 2.73B | 2.32B |
| EPS Basic | 0.76 | 5.27 | 0.94 | 0.74 | 0.70 |
| Normalized Basic EPS | 0.65 | 0.68 | 0.70 | 0.65 | 0.52 |
| EPS Diluted | 0.76 | 5.26 | 0.94 | 0.74 | 0.70 |
| Normalized Diluted EPS | 0.65 | 0.68 | 0.69 | 0.65 | 0.51 |
| Average Basic Shares Outstanding | 1.74B | 1.75B | 1.74B | 1.75B | 1.74B |
| Average Diluted Shares Outstanding | 1.75B | 1.75B | 1.75B | 1.75B | 1.75B |
| Dividend Per Share | 0.59 | 0.59 | 0.55 | 0.55 | 0.55 |
| Payout Ratio | 77.43% | 10.38% | 58.32% | 73.81% | 78.12% |